Precipio, Inc.

Precipio, Inc. is a healthcare biotechnology company focused on improving cancer diagnostics, particularly for hematologic malignancies, to combat disease misdiagnosis. The company aims to enhance diagnostic accuracy and accessibility while building a sustainable business model that supports ongoing innovation. This is achieved through a combination of clinical laboratory services and proprietary diagnostic product development. Precipio's integrated operating structure allows its service business to function as a self-funded research and development (R&D) unit, enabling rapid and cost-efficient innovation. This structure allows the R&D team to evaluate, refine, and validate diagnostic products during routine clinical testing, generating clinical data, operational experience, and specimen access at incremental cost. Precipio operates with a single operating segment but has two complementary business divisions. The Pathology Services Division provides specialized cancer diagnostic testing services to physicians, hospitals, and laboratories. This division generates revenue and develops expertise in oncology diagnostics. It delivers specialized diagnostic testing primarily focused on hematologic cancers, including molecular diagnostics, cytogenetics, and related advanced laboratory analyses. Precipio receives patient samples, such as blood and biopsies, from clinics and hospitals, conducts diagnostic analyses, and provides pathology reports to physicians regarding the nature of the patient's disease.